ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0653

Impact of Lupus Nephritis on Neuropsychiatric SLE Outcomes

Pu-Jun Fang1, Ping Hsuan Kuo2 and Chun Chi Lu1, 1Tri-service general hospital, Taipei, Taiwan (Republic of China), 2Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China)

Meeting: ACR Convergence 2024

Keywords: Lupus nephritis, neuropsychiatric disorders, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with diverse organ involvement, notably affecting the kidneys and nervous system. Lupus nephritis (LN) and neuropsychiatric SLE (NPSLE) are severe complications associated with increased morbidity and mortality. This retrospective study analyzes data from SLE patients with newly diagnosed NPSLE to explore the correlation between LN and NPSLE, focusing on clinical outcomes and potential predictive factors.

Methods: We retrospectively reviewed medical records from SLE patients with NPSLE at Tri-Service Hospital from November 2005 to December 2023. Data on demographic information, clinical manifestations, laboratory tests, Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI), complications, treatment, and mortality were collected.

Results: Our study included 48 NPSLE patients, with 32 meeting the criteria for LN diagnosis. NPSLE patients were categorized into LN+ (with lupus nephritis) and LN− (without lupus nephritis) groups. The LN+ group had a higher SELENA-SLEDAI score (p=0.001). Regarding hospitalization, the LN+ group (mean: 26.3 days) exceeded the LN− group (mean: 11.9 days) (p=0.001). The LN+ group also had a higher percentage of intensive care unit (ICU) admission (40.6% vs. 6.3%, p=0.018) and mechanical ventilation use (31.3% vs. 0.0%, p=0.020). Although the LN+ group showed higher infectious complications (46.9%) compared to the LN− group (18.8%), it did not reach statistical significance (p = 0.058). However, the LN+ group’s elevated mortality rate (25.8%) achieved statistical significance compared to the LN− group (0.0%) (p = 0.038).

Conclusion: This study underscores the substantial impact of LN on the clinical outcomes of NPSLE, revealing increased lupus activity, prolonged hospitalization, higher ICU admissions, greater use of mechanical ventilation, and a higher mortality rate in the LN+ group compared to the LN− group.

Supporting image 1

Population characteristics and neuropsychiatric (NP) manifestation in neuropsychiatric systemic lupus erythematosus (NPSLE) patients with and without lupus nephritis (LN)

Supporting image 2

Seroimmunological abnormalities in neuropsychiatric systemic lupus erythematosus (NPSLE) patients with and without lupus nephritis (LN)

Supporting image 3

Differences in outcomes between patients with NPSLE with and without LN


Disclosures: P. Fang: None; P. Kuo: None; C. Lu: None.

To cite this abstract in AMA style:

Fang P, Kuo P, Lu C. Impact of Lupus Nephritis on Neuropsychiatric SLE Outcomes [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/impact-of-lupus-nephritis-on-neuropsychiatric-sle-outcomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-lupus-nephritis-on-neuropsychiatric-sle-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology